In first-line dMMR/MSI-H metastatic colorectal cancer, mFOLFOX6/bevacizumab plus atezolizumab improved progression-free survival vs atezolizumab alone (HR 0.439; 82 patients). Grade ≥3 adverse events: 34 vs 18 patients. FFX/bev-only arm closed early.
RCTn = 102
Rocha Lima et al. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer